Blog / Archives
MO Players Take Profits Again in Biotech-Risk Off: AGIO, BLUE, JUNO, PBYI, KITE, ZIOP
NASDAQ at 4667 up 0.27% XBI at $194.4 down 2.88% Clinical Stage Immuno-oncology Stocks Hit Hard Again Momentum traders took money off the table for the second time in three days. Most large cap...
JPMorgan Healthcare Conference Notes #4: Next Gen Sequencing (NGS)
Seminar: Harnessing the Power of Next Gen Sequencing: The View from Industry 1/12/15 A panel of leading entrepreneurial R&D executives presented their outlook and issues on the future of Next...
MOmentum Shift in BIOtech Today: XBI off 3.25%.. Update -1
Update Next Day...Green Screen in Biotech...1/16...Complete reversal all up XBI at $197.95 UP 3% AGIO up 3.6%, BLUE up 4.78%, JUNO up 12.4%, KITE up 10.2%, NLNK up 2.4%, PBYI up 9.4%, ZIOP up 1.76%...
Rayno Small Cap Picks: FCSC, PACB Update-1
Update 1/15 Fibrocell Science has moved another 3.5% probably related to recent moves of Intrexon (XON) up 3% today. Both FCSC and XON have Third Security LLC as major holder, PACB is down 4.78% on...
JPMorgan Conference #3: Emerging Clinical Dx Companies- AXDX, GNMK
Next Generation Clinical Diagnostic Systems We sat in on presentations for two innovative clinical diagnostic companies that have platform products serving big potential markets. Although it may be...
JPMorgan Conference Notes #2: Biotech Stocks Surge to New Highs Then Sell Off on Energy/Materials Weakness
FBT up 2.4% to $108 then drifts back to 107; NASDAQ flat 4661 DOW bounced around in 425 point range. Mixed market among biotech stocks after NASDAQ and S&P sell off; momentum eases. Mid-cap...
JPMorgan Healthcare Conference Notes #1: Sequencing Picks Romp-FMI
Sequencing Remains Hot-Roche (RHHBY) Deal With Foundation Medicine (FMI) Worth $1.1B Targeted Oncology Therapy-Molecular information from pathways and biomarkers e.g. PDL-1 RNA based immunotherapy...
Rayno Life Science Movers on a 3% Up Day
Life Science Stocks Up For the Year Biotech stocks resumed their upward move near all time highs in FBT and XBI.We will review many of the stocks in our portfolios at the JPMorgan Conference next...
2015 Biotech Stock Preview: Rhythms of the “PermaBull”
2015: Another Good Year Unless "Something Happens" Life Science stocks had another big year in 2014 up 48% tracking gains for the overall healthcare sector up 35%. Over 10 years the return is 300%!...
Biotechs Avoid Harsh Sell-Off: Many Stocks in the Green
XLE off 4%, NASDAQ Off 1.57%, Biotech Mainly In The Green After Close: Financials and Materials also hit hard down over 2% Biotech stocks remain a safe harbor in a stormy market freaked out by the...